Mirna Samara Dié Alves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mirna Samara Dié Alves has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Raquel Nascimento das Neves
Laboratório de Farmacologia e Bioquímica do Câncer (LabCancer), Departamento de Farmacologia, Centro de Ciências Biológicas (CCB), Universidade Federal de Santa Catarina (UFSC), Florianópolis, Santa Catarina, 88040-900, Brazil; Greehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX, 78229, USA
2 shared publications - Ana Carla Diógenes Suassuna Bezerra
UFERSA
1 shared publication - Angela Maria Casaril
Technologic Development Center, Biotechnology Unit, Neurobiotechnology Research Group, Federal University of Pelotas, Pelotas, RS, Brazil
1 shared publication Bruna Silveira Pacheco
Laboratory of Lipidomics and Bioorganic, Bioforensics Research Group, Federal University of Pelotas, RS, 96010-900, Brazil
1 shared publication- Caroline Carapina da Silva
Laboratory of Lipidomics and Bioorganic, Bioforensics Research Group, Federal University of Pelotas, RS, 96010-900, Brazil
1 shared publication Claudio Martin Pereira de Pereira
Laboratory of Lipidomics and Bioorganic, Bioforensics Research Group, Federal University of Pelotas, RS, 96010-900, Brazil
1 shared publication
Latest Publications
- 2 December 2025
- Published by Elsevier in Veterinary Parasitology
- Vol. 342, 110664
In vitro and in silico evaluation of nematicidal lectin compounds from Artocarpus heterophyllus seeds targeting gastrointestinal helminths
- 2 December 2025
- Published by Elsevier in Veterinary Parasitology
- Vol. 342, 110664
In vitro and in silico evaluation of nematicidal lectin compounds from Artocarpus heterophyllus seeds targeting gastrointestinal helminths
- Open Access
Evaluation of the Association of Recombinant Proteins NanH and PknG from Corynebacterium pseudotuberculosis Using Different Adjuvants as a Recombinant Vaccine in Mice
Caseous lymphadenitis is a chronic contagious disease that causes economic losses worldwide. Treatments are ineffective, thus demonstrating the importance of vaccination. In this study, rNanH and rPknG proteins from Corynebacterium pseudotuberculosis were associated with saponin or aluminum hydroxide adjuvants. Three experimental groups (10 animals each) were immunized with sterile 0.9% saline solution (G1), rNanH + rPknG + Saponin (G2), rNanH + rPknG + Al(OH)3 (G3). The mice received two vaccine doses 21 days apart. Animals were challenged 21 days after the last immunization and evaluated for 50 days, with endpoint criteria applied when needed. The total IgG production levels of the experimental groups increased significantly on day 42 when compared to the control (p < 0.05). When tested against rNanH, G2 had a better rate of anti-rNanH antibodies compared to G3. In the anti-rPknG ELISA, the levels of total IgG, IgG1, and IgG2a antibodies were higher in G2. The vaccines generated partial protection, with 40% of the animals surviving the challenge. The association of recombinant NanH and PknG proteins led to promising protection rates in mice, and although using different adjuvants did not interfere with the survival rate, it influenced the immune response generated by the vaccine formulations.
Open AccessEvaluation of the Association of Recombinant Proteins NanH and PknG from Corynebacterium pseudotuberculosis Using Different Adjuvants as a Recombinant Vaccine in Mice
Caseous lymphadenitis is a chronic contagious disease that causes economic losses worldwide. Treatments are ineffective, thus demonstrating the importance of vaccination. In this study, rNanH and rPknG proteins from Corynebacterium pseudotuberculosis were associated with saponin or aluminum hydroxide adjuvants. Three experimental groups (10 animals each) were immunized with sterile 0.9% saline solution (G1), rNanH + rPknG + Saponin (G2), rNanH + rPknG + Al(OH)3 (G3). The mice received two vaccine doses 21 days apart. Animals were challenged 21 days after the last immunization and evaluated for 50 days, with endpoint criteria applied when needed. The total IgG production levels of the experimental groups increased significantly on day 42 when compared to the control (p < 0.05). When tested against rNanH, G2 had a better rate of anti-rNanH antibodies compared to G3. In the anti-rPknG ELISA, the levels of total IgG, IgG1, and IgG2a antibodies were higher in G2. The vaccines generated partial protection, with 40% of the animals surviving the challenge. The association of recombinant NanH and PknG proteins led to promising protection rates in mice, and although using different adjuvants did not interfere with the survival rate, it influenced the immune response generated by the vaccine formulations.
- Open Access
- 11 February 2020
- Published by Springer Nature in Parasites & Vectors
- Vol. 13 (1) , 1-13
Antiparasitic activity of furanyl N-acylhydrazone derivatives against Trichomonas vaginalis: in vitro and in silico analyses
Background: Trichomonas vaginalisis the causative agent of trichomoniasis, which is one of the most common sexually transmitted diseases worldwide. Trichomoniasis has a high incidence and prevalence and is associated with serious complications such as HIV transmission and acquisition, pelvic inflammatory disease and preterm birth. Although trichomoniasis is treated with oral metronidazole (MTZ), the number of strains resistant to this drug is increasing (2.5–9.6%), leading to treatment failure. Therefore, there is an urgent need to find alternative drugs to combat this disease.Methods: Herein, we report thein vitroandin silicoanalysis of 12 furanylN-acylhydrazone derivatives (PFUR 4, a-k) againstTrichomonas vaginalis.Trichomonas vaginalisATCC 30236 isolate was treated with seven concentrations of these compounds to determine the minimum inhibitory concentration (MIC) and 50% inhibitory concentration (IC50). In addition, compounds that displayed anti-T. vaginalisactivity were analyzed using thiobarbituric acid reactive substances (TBARS) assay and molecular docking. Cytotoxicity analysis was also performed in CHO-K1 cells.Results: The compounds PFUR 4a and 4b, at 6.25 µM, induced complete parasite death after 24 h of exposure with IC50of 1.69 µM and 1.98 µM, respectively. The results showed that lipid peroxidation is not involved in parasite death. Molecular docking studies predicted strong interactions of PFUR 4a and 4b withT. vaginalisenzymes, purine nucleoside phosphorylase, and lactate dehydrogenase, while only PFUR 4b interactedin silicowith thioredoxin reductase and methionine gamma-lyase. PFUR 4a and 4b led to a growth inhibition (< 20%) in CHO-K1 cells that was comparable to the drug of choice, with a promising selectivity index (> 7.4).Conclusions: Our results showed that PFUR 4a and 4b are promising molecules that can be used for the development of new trichomonacidal agents forT. vaginalis.
- 11 February 2020
- Published by Springer Nature in Parasites & Vectors
- Vol. 13 (1) , 1-13
Open AccessAntiparasitic activity of furanyl N-acylhydrazone derivatives against Trichomonas vaginalis: in vitro and in silico analyses
Background: Trichomonas vaginalisis the causative agent of trichomoniasis, which is one of the most common sexually transmitted diseases worldwide. Trichomoniasis has a high incidence and prevalence and is associated with serious complications such as HIV transmission and acquisition, pelvic inflammatory disease and preterm birth. Although trichomoniasis is treated with oral metronidazole (MTZ), the number of strains resistant to this drug is increasing (2.5–9.6%), leading to treatment failure. Therefore, there is an urgent need to find alternative drugs to combat this disease.Methods: Herein, we report thein vitroandin silicoanalysis of 12 furanylN-acylhydrazone derivatives (PFUR 4, a-k) againstTrichomonas vaginalis.Trichomonas vaginalisATCC 30236 isolate was treated with seven concentrations of these compounds to determine the minimum inhibitory concentration (MIC) and 50% inhibitory concentration (IC50). In addition, compounds that displayed anti-T. vaginalisactivity were analyzed using thiobarbituric acid reactive substances (TBARS) assay and molecular docking. Cytotoxicity analysis was also performed in CHO-K1 cells.Results: The compounds PFUR 4a and 4b, at 6.25 µM, induced complete parasite death after 24 h of exposure with IC50of 1.69 µM and 1.98 µM, respectively. The results showed that lipid peroxidation is not involved in parasite death. Molecular docking studies predicted strong interactions of PFUR 4a and 4b withT. vaginalisenzymes, purine nucleoside phosphorylase, and lactate dehydrogenase, while only PFUR 4b interactedin silicowith thioredoxin reductase and methionine gamma-lyase. PFUR 4a and 4b led to a growth inhibition (< 20%) in CHO-K1 cells that was comparable to the drug of choice, with a promising selectivity index (> 7.4).Conclusions: Our results showed that PFUR 4a and 4b are promising molecules that can be used for the development of new trichomonacidal agents forT. vaginalis.
- Open Access
- 1 March 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 111, 367-377
Antiparasitic activity of synthetic curcumin monocarbonyl analogues against Trichomonas vaginalis
- 1 March 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 111, 367-377
Open AccessAntiparasitic activity of synthetic curcumin monocarbonyl analogues against Trichomonas vaginalis